Skip to main
ZLAB
ZLAB logo

ZLAB Stock Forecast & Price Target

ZLAB Analyst Ratings

Based on 11 analyst ratings
Buy
Strong Buy 18%
Buy 73%
Hold 9%
Sell 0%
Strong Sell 0%

Bulls say

Zai Lab Ltd's positive outlook is bolstered by the improved efficacy and safety of its investigational therapies, particularly ZL-1310, which has demonstrated strong potential in treating advanced-stage small cell lung cancer (SCLC), leading to a recent spike in stock performance following favorable first-in-human data. The company's diverse portfolio, including proprietary drug candidates like ZL-2306, ZL-2401, and ZL-2301, addresses significant unmet medical needs in oncology and infectious diseases, suggesting substantial market opportunities that may not yet be fully reflected in its current valuation. Furthermore, the competitive landscape, highlighted by recent FDA approvals for similar therapies, emphasizes the importance of Zai Lab's advancements and their potential to capture market share in the growing biopharmaceutical sector.

Bears say

Zai Lab Ltd. faces significant challenges in successfully commercializing its products due to extensive competition from larger pharmaceutical companies that possess robust sales and marketing resources, potentially leading to higher risks, longer timelines, and increased costs for Zai Lab. Additionally, the company has limited experience in product commercialization, which further complicates its ability to compete effectively in a crowded market. Lastly, uncertainties within the Chinese legal system could negatively impact Zai Lab's operational stability and investment attractiveness, adding to the concerns surrounding its market position and future growth prospects.

ZLAB has been analyzed by 11 analysts, with a consensus rating of Buy. 18% of analysts recommend a Strong Buy, 73% recommend Buy, 9% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Zai Lab Ltd. and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Zai Lab Ltd. (ZLAB) Forecast

Analysts have given ZLAB a Buy based on their latest research and market trends.

According to 11 analysts, ZLAB has a Buy consensus rating as of Jul 3, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $58.79, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $58.79, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Zai Lab Ltd. (ZLAB)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.